Effectiveness of an NK1 Antagonist in PTSD.

Trial Profile

Effectiveness of an NK1 Antagonist in PTSD.

Phase of Trial: Phase II

Latest Information Update: 11 Mar 2013

At a glance

  • Drugs Vofopitant (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 11 Mar 2013 Additional lead trial centre added as reported by ClinicalTrials.gov record.
    • 14 Apr 2009 Planned number of patients changed from 52 to 47, additional lead trial centre identified, actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 14 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top